860 related articles for article (PubMed ID: 27037651)
41. Human cytomegalovirus (CMV) UL97 D605E mutation has a higher prevalence in infants with primary CMV infection compared with transplant recipients with CMV recurrence.
Sun J; Cao G; Zhang L; Zhang Y; Zhao Z; Hu J; Ji Y
Transplant Proc; 2012 Dec; 44(10):3022-5. PubMed ID: 23195018
[TBL] [Abstract][Full Text] [Related]
42. Does valganciclovir hydrochloride (valcyte) provide effective prophylaxis against cytomegalovirus infection in liver transplant recipients?
Jain A; Orloff M; Kashyap R; Lansing K; Betts R; Mohanka R; Menegus M; Ryan C; Bozorgzadeh A
Transplant Proc; 2005 Sep; 37(7):3182-6. PubMed ID: 16213344
[TBL] [Abstract][Full Text] [Related]
43. Combination antiviral therapy for ganciclovir-resistant cytomegalovirus infection in solid-organ transplant recipients.
Mylonakis E; Kallas WM; Fishman JA
Clin Infect Dis; 2002 May; 34(10):1337-41. PubMed ID: 11981729
[TBL] [Abstract][Full Text] [Related]
44. Management of ganciclovir resistance cytomegalovirus infection with CMV hyperimmune globulin and leflunomide in seven cardiothoracic transplant recipients and literature review.
Santhanakrishnan K; Yonan N; Iyer K; Callan P; Al-Aloul M; Venkateswaran R
Transpl Infect Dis; 2022 Feb; 24(1):e13733. PubMed ID: 34534396
[TBL] [Abstract][Full Text] [Related]
45. Risk factors for cytomegalovirus viremia and disease developing after prophylaxis in high-risk solid-organ transplant recipients.
Freeman RB; Paya C; Pescovitz MD; Humar A; Dominguez E; Washburn K; Blumberg E; Alexander B; Heaton N;
Transplantation; 2004 Dec; 78(12):1765-73. PubMed ID: 15614149
[TBL] [Abstract][Full Text] [Related]
46. Allograft rejection predicts the occurrence of late-onset cytomegalovirus (CMV) disease among CMV-mismatched solid organ transplant patients receiving prophylaxis with oral ganciclovir.
Razonable RR; Rivero A; Rodriguez A; Wilson J; Daniels J; Jenkins G; Larson T; Hellinger WC; Spivey JR; Paya CV
J Infect Dis; 2001 Dec; 184(11):1461-4. PubMed ID: 11709790
[TBL] [Abstract][Full Text] [Related]
47. Early ganciclovir therapy effectively controls viremia and avoids the need for cytomegalovirus (CMV) prophylaxis in renal transplant patients with cytomegalovirus antigenemia.
Gotti E; Suter F; Baruzzo S; Perani V; Moioli F; Remuzzi G
Clin Transplant; 1996 Dec; 10(6 Pt 1):550-5. PubMed ID: 8996777
[TBL] [Abstract][Full Text] [Related]
48. Use of high-dose ganciclovir for the treatment of cytomegalovirus replication in solid organ transplant patients with ganciclovir resistance-inducing mutations.
Gracia-Ahufinger I; Gutiérrez-Aroca J; Cordero E; Vidal E; Cantisán S; del Castillo D; Martín-Gandul C; Rivero A; Torre-Cisneros J
Transplantation; 2013 Apr; 95(8):1015-20. PubMed ID: 23407543
[TBL] [Abstract][Full Text] [Related]
49. Oral ganciclovir versus valganciclovir for cytomegalovirus prophylaxis in high-risk liver transplant recipients.
Brady RL; Green K; Frei C; Maxwell P
Transpl Infect Dis; 2009 Apr; 11(2):106-11. PubMed ID: 19054381
[TBL] [Abstract][Full Text] [Related]
50. Cytomegalovirus disease among donor-positive/recipient-negative lung transplant recipients in the era of valganciclovir prophylaxis.
Mitsani D; Nguyen MH; Kwak EJ; Silveira FP; Vadnerkar A; Pilewski J; Crespo M; Toyoda Y; Bermudez C; Clancy CJ
J Heart Lung Transplant; 2010 Sep; 29(9):1014-20. PubMed ID: 20598582
[TBL] [Abstract][Full Text] [Related]
51. Effect of delaying prophylaxis against CMV in D+/R- solid organ transplant recipients in the development of CMV-specific cellular immunity and occurrence of late CMV disease.
San-Juan R; Navarro D; García-Reyne A; Montejo M; Muñoz P; Carratala J; Len O; Fortun J; Muñoz-Cobo B; Gimenez E; Eworo A; Sabe N; Meije Y; Martin-Davila P; Andres A; Delgado J; Jimenez C; Amat P; Fernández-Ruiz M; López-Medrano F; Lumbreras C; Aguado JM; ;
J Infect; 2015 Nov; 71(5):561-70. PubMed ID: 26183297
[TBL] [Abstract][Full Text] [Related]
52. Relapsing cytomegalovirus infection in solid organ transplant recipients.
Shanahan A; Malani PN; Kaul DR
Transpl Infect Dis; 2009 Dec; 11(6):513-8. PubMed ID: 19735385
[TBL] [Abstract][Full Text] [Related]
53. Sequence analysis of UL54 and UL97 genes and evaluation of antiviral susceptibility of human cytomegalovirus isolates obtained from kidney allograft recipients before and after treatment.
Mousavi-Jazi M; Hökeberg I; Schloss L; Zweygberg-Wirgart B; Grillner L; Linde A; Brytting M
Transpl Infect Dis; 2001 Dec; 3(4):195-202. PubMed ID: 11844151
[TBL] [Abstract][Full Text] [Related]
54. Primary response against cytomegalovirus during antiviral prophylaxis with valganciclovir, in solid organ transplant recipients.
La Rosa C; Limaye AP; Krishnan A; Blumstein G; Longmate J; Diamond DJ
Transpl Int; 2011 Sep; 24(9):920-31. PubMed ID: 21672050
[TBL] [Abstract][Full Text] [Related]
55. Cost of prophylaxis in the management of cytomegalovirus infection in solid organ transplant recipients.
Oppenheimer F; Gonzalez-Molina M; Rubio M
Clin Transplant; 2007; 21(4):441-8. PubMed ID: 17645702
[TBL] [Abstract][Full Text] [Related]
56. Impact of donor and recipient cytomegalovirus serology on long-term survival of heart transplant recipients.
Mabilangan C; Preiksaitis JK; Cervera C;
Transpl Infect Dis; 2019 Feb; 21(1):e13015. PubMed ID: 30358023
[TBL] [Abstract][Full Text] [Related]
57. A new strategy of delayed long-term prophylaxis could prevent cytomegalovirus disease in (D+/R-) solid organ transplant recipients.
San Juan R; Yebra M; Lumbreras C; López-Medrano F; Lizasoain M; Meneu JC; Delgado J; Andrés A; Aguado JM
Clin Transplant; 2009; 23(5):666-71. PubMed ID: 19689451
[TBL] [Abstract][Full Text] [Related]
58. Efficacy and safety of low-dose valganciclovir in the prevention of cytomegalovirus disease in adult liver transplant recipients.
Park JM; Lake KD; Arenas JD; Fontana RJ
Liver Transpl; 2006 Jan; 12(1):112-6. PubMed ID: 16382458
[TBL] [Abstract][Full Text] [Related]
59. Extended Low-Dose Valganciclovir Is Effective Prophylaxis Against Cytomegalovirus in High-Risk Kidney Transplant Recipients With Near-Complete Eradication of Late-Onset Disease.
Fayek SA; Beshears E; Lieber R; Alvey N; Sauer A; Poirier J; Hollinger EF; Olaitan OK; Jensik S; Geyston J; Brokhof MM; Hodowanec AC; Hertl M; Simon DM
Transplant Proc; 2016; 48(6):2056-2064.e1. PubMed ID: 27569944
[TBL] [Abstract][Full Text] [Related]
60. [Investigation of Ganciclovir Resistance in Cytomegalovirus Isolates by Phenotypic and Genotypic Methods].
Sarınoğlu RC; Çolak D; Küpesiz OA; Kuşkucu MA; Yalçın K; Sağlık İ; Mutlu D; Midilli K; Peker BO; Özhak B; Özkul A; Foldes K
Mikrobiyol Bul; 2023 Jul; 57(3):401-418. PubMed ID: 37462304
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
